News & Events
Published On: 3/8/2022
TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation
DURHAM, N.C., March 8, 2022 /PRNewswire/ -- A new TARGET-IBD study analysis shows one-third of patients with inflammatory bowel disease (IBD) did not have a record of objective disease activity assessment or therapeutic drug monitoring (TDM) prior to a biologic therapy dose change or discontinuation. The study was conducted by Target RWE, a leading real-world evidence (RWE) solutions company for the healthcare industry.
Results found 32.5% of patients who underwent a dose escalation and 20.6% of patients who had biologic discontinuation did not have any objective assessment or therapeutic drug monitoring (TDM) performed in the 12 weeks prior to the date of therapeutic change.
"The TARGET-IBD analysis suggests a significant portion of IBD patients do not undergo objective assessment prior to biologic therapy change or discontinuation, and further suggests clinicians may be relying less on objective data in certain situations," said Benjamin Click, MD, MS, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine and first author on the study. "There are several possible explanations to this finding, however, reasons for these treatment patterns should be further explored."
Published in the peer-reviewed BMC Gastroenterology, Objective Disease Activity Assessment and Therapeutic Drug Monitoring Prior to Biologic Therapy Changes in Routine Inflammatory Bowel Disease Clinical Practice: TARGET-IBD studied over 2,100 IBD patients from 34 academic and community centers throughout the U.S. between June 2017 and October 2019. The analysis captured patients receiving biologic therapy who had either a dose change or biologic discontinuation for lack of efficacy.
"Given the recent advancements in IBD treatment, it may be tempting for providers to switch from one therapy to another when their patient doesn't see an improvement in symptoms. This study highlights that there is a need for further assessment in many patients with IBD to help guide treatment approaches," said Edward Barnes, MD, MPH, Assistant Professor of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, and co-author of the study.
TARGET-IBD is an ongoing longitudinal, observational study of more than 4,800 adult and pediatric patients with IBD receiving usual care from academic and community centers throughout the U.S. Real-world data is collected from consented participants, who may also provide patient-reported outcome measures and biospecimens. Learn more about Target RWE's IBD publications here.
About Target RWE
As the industry's best-in-class, complete real world evidence (RWE) solution, Target RWE is a distinctly collaborative enterprise that unifies real world data (RWD) sets and advanced RWE analytics in an integrated community, shifting the paradigm in healthcare for how decisions are made to improve lives.
Target RWE sources unique, connected data sets across multiple therapeutic areas representing granular data from diverse patients in academic and community settings. Our rigorous, interactive, and advanced RWE analytics extract deep insights from RWD to answer important questions in healthcare. Target RWE brings together the brightest minds in healthcare through an unmatched community of key opinion leaders, patients, and healthcare stakeholders in a collaborative and dynamic model. www.targetrwe.com
984.234.0268 ext 205
03/08/2023Ewa Kleczyk, PhD Featured on CIO Views Cover for March – A Memento to Women’s History Month & International Women’s Day
02/28/2023Longest Running Real World Dermatology Registry, TARGET-DERM, Offers Deep Insight into Complex Diseases
01/11/2023Target RWE Launches 35 New Disease State Registries in Complex Indications with High Unmet Medical Needs and Rapidly Evolving Therapies
11/04/2022New TARGET-NASH Real World Data Show Non-Alcoholic Fatty Liver Disease Severity and Gender Linked to Disparities in Polypharmacy
10/18/2022Target RWE and the American Association for the Study of Liver Diseases Announce Research Agreement for Cirrhosis Quality Collaborative